Mayne Pharma to sell new heart disease meds in US

Company News

by David Chau

Mayne Pharma Group Limited (ASX:MYX) has been granted US FDA approval for its new generic dofetlide capsules.

The company says its dofetlide capsules are the first generic alternative to Pfizer’s Tikosyn, which is medication used to prevent irregular heartbeats such as atrial flutter.

Mayne Pharma says that it has also been awarded 180 days of market exclusivity in the US for its new product.

The company also has an agreement with another company, Johnson Matthey Inc, to share profits equally from sales of this product.

Mayne Pharma reported a net profit of $17.9 million at 31 December 2015.

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?